Terkko Navigator / Hematology/ Feeds

Successful retreatment with 3-week rituximab-bendamustine with high-dose dexamethasone in patients with relapsed/refractory mantle cell lymphoma

A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding

New wrinkle on deubiquitination in B-cell lymphoma

Stressed about erythropoiesis: EBI macrophages

Of mice and men: genes relevant to thrombosis and bleeding

Mechanisms of receptor shedding in platelets

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice

Unique dependence on Sos1 in KrasG12D-induced leukemogenesis

Monocyte-derived macrophages expand the murine stress erythropoietic niche during the recovery from anemia

Unrelated donor vs HLA-haploidentical {alpha}/{beta} T-cell- and B-cell-depleted HSCT in children with acute leukemia

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients

Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis

Stahl A, Joyal J-S, Chen J, et al. SOCS3 is an endogenous inhibitor of pathologic angiogenesis. Blood. 2012;120(14):2925-2929.

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways

Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective

Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials.

Blood donor deferral policies across Europe and characteristics of men whohave sex with men screened for human immunodeficiency virus in bloodestablishments: data from the European Men-who-have-sex-with-men Internet Survey (EMIS).

Flow cytometry analysis of platelet populations: usefulness for monitoringthe storage lesion in pooled buffy-coat platelet concentrates.

Molecular basis of the Duffy blood group system.

Variant Creutzfeldt-Jakob disease deferral in Canada: impact of stop dates.

FUT1 mutations responsible for the H-deficient phenotype in the Polish population, including the first example of an abolished start codon.

Low-dose erythropoietin treatment is not associated with clinical benefits in severely anaemic Jehovah's Witnesses: a plea for a change.

Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.

The Bleeding Assessment Tool and laboratory data in the characterisation of a female with inherited haemophilia A.

Asymptomatic infections in blood donors harbouring Plasmodium: an invisible risk detected by molecular and serological tools.

Molecular genetic analysis of the F11 gene in 14 Turkish patients with factor XI deficiency: identification of novel and recurrent mutations and their inheritance within families.

Red blood cell use in Switzerland: trends and demographic challenges.

Tranexamic acid use and risk of thrombosis in regular users ofantithrombotics undergoing primary total knee arthroplasty: a prospectivecohort study.

Preserved in vitro metabolic and functional characteristics of double-dose apheresis platelet concentrates photochemically treated with amotosalen and ultraviolet A light.

Leucocyte cytokines dominate platelet cytokines overtime in non-leucoreduced platelet components.

"Non-remunerated donation": a tautology?

Non‐Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group

Intracranial Response to Anti‐Programmed Death 1 Therapy in a Patient with Metastatic Non‐Small Cell Lung Cancer with Leptomeningeal Carcinomatosis

Tumor Lysis Syndrome in the 21st Century: To Recreate Risk Factors and Prognosis?

In Reply

Pertuzumab: Getting the Balance Right

In Reply

Volume 23 Author Index

Volume 23 Acknowledgments

Conflict of Interest: An Ethical Firestorm with Consequences for Cancer Research

Conflicts of Interest, Baselga, and Clinical Trialists

Tumor Molecular Testing Guides Anti‐PD‐1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants

Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer

Randomized, Open‐Label Phase II Study Comparing Capecitabine‐Cisplatin Every 3 Weeks with S‐1‐Cisplatin Every 5 Weeks in Chemotherapy‐Naïve Patients with HER2‐Negative Advanced Gastric Cancer: OGSG1105, HERBIS‐4A Trial

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial

Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker